Profil
Muhammad Al-Hajj formerly worked at GSK Plc, as Senior Director-Biology & Trans Med from 2009 to 2015, Sanford Burnham Prebys Medical Discovery Institute, as VP-Drug Discovery & Translational Medicine from 2015 to 2017, Autolus Ltd., as Senior Vice President-Translational Sciences, and IO Biotech, Inc., as Chief Scientific Officer from 2021 to 2024.
Dr. Al-Hajj received his doctorate degree from the University of Michigan Comprehensive Cancer Center.
Anciens postes connus de Muhammad Al-Hajj
| Sociétés | Poste | Fin |
|---|---|---|
| IO BIOTECH, INC. | Directeur Technique/Scientifique/R&D | 01/01/2024 |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Corporate Officer/Principal | 01/06/2017 |
| GSK PLC | Corporate Officer/Principal | 01/04/2015 |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Corporate Officer/Principal | - |
Formation de Muhammad Al-Hajj
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Conducts medical research | Health Services |
University of Michigan Comprehensive Cancer Center
University of Michigan Comprehensive Cancer Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
IO Biotech, Inc.
IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
















